Fulcrum Asset Management’s Indivior Pharmaceuticals INDV Stock Holding History

Fulcrum Asset Management’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.25K	Buy	+200	New	+$7.25K	﹤0.01%	696

Other funds holding INDV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fulcrum Asset Management's INDV Position: Q2 2026 in Review

Fulcrum Asset Management opened a new position in Indivior Pharmaceuticals (INDV) in Q2 2026: 200 shares worth $8.25K. The stake represents ﹤0.01% of the portfolio and ranks #696 among its holdings.

336 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

Fulcrum Asset Management held 200 shares of Indivior Pharmaceuticals worth $8.25K as of Q2 2026.
Indivior Pharmaceuticals was a new Fulcrum Asset Management position in Q2 2026.
Indivior Pharmaceuticals made up ﹤0.01% of Fulcrum Asset Management's portfolio in Q2 2026, its #696 holding.
336 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Fulcrum Asset Management's 13F filing for Q2 2026, filed 18 Aug 2026.